aibio
Distress ·
Vaccinex delays annual report for fiscal year ended December 31, 2024
The company cited delays in completing its financial statements. It expects to file within the extension period of up to fifteen calendar days under Rule 12b-25.
VCNX Vaccinex, Inc.
Vaccinex (VCNX) news VCNX delisting news
Latest Vaccinex news
- Listings
Vaccinex files Form 25 to voluntarily withdraw its stock from Nasdaq
The Rochester, New York company filed the notice on March 17, 2025. It covers its common stock, par value $0.0001 per share.
Vaccinex annual financials
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $601,000 | $570,000 |
| Research and development | $12.5 million | $16.6 million |
| Net income (loss) | -$18.6 million | -$20.3 million |
| Cash from operations | -$16.2 million | -$21.4 million |
| Cash and equivalents | $1.1 million | $1.5 million |
Questions about Vaccinex
Was Vaccinex delisted?
Our latest story on this, dated Mar 17, 2025: "Vaccinex files Form 25 to voluntarily withdraw its stock from Nasdaq". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Vaccinex?
Vaccinex, Inc. trades under the ticker VCNX on OTC.
Where is Vaccinex listed?
Vaccinex, Inc. is listed on OTC.
What is the SEC CIK of Vaccinex?
The SEC Central Index Key (CIK) for Vaccinex, Inc. is 1205922. Its filings are on SEC EDGAR.
How many shares does Vaccinex have outstanding?
2,676,637 shares as of 2025-04-11, per the cover page of its 10-K filed 2025-04-15.
Which country or territory is Vaccinex listed under?
Our directory records Vaccinex, Inc. under United States.
What does Vaccinex do?
Our directory classifies Vaccinex, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Vaccinex?
The ISIN recorded for Vaccinex, Inc. is US9186403013.
Does aibio.space cover Vaccinex?
aibio.space lists Vaccinex, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Vaccinex incorporated?
SEC records list its state or country of incorporation as DE.
What was Vaccinex's revenue last year?
$601,000 for the fiscal year ended Dec 31, 2024, as reported to the SEC.
Is Vaccinex profitable?
Vaccinex, Inc. reported a net loss of $18.6 million for the fiscal year ended Dec 31, 2024, and used $16.2 million of cash in operations, per its annual report to the SEC.
How much does Vaccinex spend on research and development?
$12.5 million in the fiscal year ended Dec 31, 2024, per its annual report.
How much cash does Vaccinex have?
$1.1 million in cash at Dec 31, 2024, per its 10-K.
What is the latest Vaccinex (VCNX) stock news?
Our latest story on Vaccinex, dated Apr 1, 2025: "Vaccinex delays annual report for fiscal year ended December 31, 2024". The company cited delays in completing its financial statements. It expects to file within the extension period of up to fifteen calendar days under Rule 12b-25. Source.
Investor discussion: Vaccinex
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Listings
Filed to end its SEC reporting. SEC Form 15-12G. Source
- Listings
Filed to remove its shares from exchange listing. SEC Form 25. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Vaccinex, Inc.
- CIK
- 1205922
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- VCNX (OTC)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 1895 MOUNT HOPE AVE, ROCHESTER, NY, 14620
- Phone
- 585-271-2700
- Shares outstanding
- 2,676,637 as of 2025-04-11 (10-K filed 2025-04-15)
- Former names
- VACCINEX INC
Recent filings
Listing details
- Company
- Vaccinex, Inc.
- Ticker
- VCNX
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US9186403013
- Last quote in directory
- 2026-10-20
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction